Exosome-Secreting Neurons are a specialized population of neurons that release extracellular vesicles (EVs), particularly exosomes (30-150 nm diameter), which play critical roles in intercellular communication within the brain. These vesicles can propagate pathological proteins and signals between neurons and glial cells, contributing to disease progression in neurodegenerative disorders.[1]
Neuronal exosome secretion represents a fundamental biological process that evolved as a mechanism for cellular communication but has been co-opted by pathological processes in diseases like Alzheimer's, Parkinson's, ALS, and Huntington's disease. Understanding this process provides crucial insights into disease mechanisms and potential therapeutic targets.
Neuronal exosomes originate from the endosomal system through a well-characterized biogenesis pathway:
Neuronal exosome release is dynamically regulated by:
Neuronal exosomes contain a diverse protein repertoire:
| Category | Examples | Function |
|---|---|---|
| Membrane proteins | NCAM, L1CAM, APP | Cell adhesion, cargo loading |
| Tetraspanins | CD63, CD81, CD9 | Exosome markers, membrane organization |
| Heat shock proteins | Hsp70, Hsp90 | Protein folding, stress response |
| Enzymes | GAPDH, PKM | Metabolic functions |
| Pathological proteins | Aβ, α-syn, tau, TDP-43 | Disease propagation |
| Synaptic proteins | Synapsin, PSD-95 | Synaptic function markers |
Neuronal exosomes shuttle genetic material between cells:
The lipid bilayer of neuronal exosomes is enriched in:
Exosome-secreting neurons are distributed throughout the central nervous system, with particularly important populations in:
The density and activity of exosome secretion varies by neuronal subtype, with some populations showing significantly higher baseline secretion rates.[6]
Exosome-secreting neurons communicate with multiple glial cell types through vesicular release:
Exosomes facilitate spread of pathological proteins across brain networks:
Exosome-secreting neurons contribute to AD progression through multiple mechanisms:
| Disease | Exosome Role | Clinical Significance |
|---|---|---|
| Alzheimer's | Aβ/tau propagation | Biomarker potential, disease progression |
| Parkinson's | α-synuclein spread | Early detection, disease progression |
| ALS | TDP-43/SOD1 transmission | Biomarker, disease staging |
| Huntington's | Mutant HTT secretion | Therapeutic target, biomarker |
| FTD | TDP-43 propagation | Biomarker potential, differential diagnosis |
Neuron-derived exosomes (NDEs) in cerebrospinal fluid and blood provide:
| Method | Advantages | Limitations |
|---|---|---|
| Ultracentrifugation | Gold standard, high purity | Time-consuming, low yield |
| Size-exclusion chromatography | Preserves cargo integrity | Requires ultracentrifugation prep |
| Immunoaffinity capture | High specificity for NDEs | Antibody-dependent, expensive |
| Precipitation (PEG) | Simple, high recovery | Lower specificity |
| Microfluidics | Fast, low sample volume | Validation needed |
Neuronal markers for capture: NCAM (Neural Cell Adhesion Molecule), L1CAM, Tau, Synaptophysin
Quek C, Hill AF. (2017). The role of extracellular vesicles in neurodegenerative diseases. Biophys Acta. 1861(11):2960-2971. 28916138. 2017. ↩︎
Hessvik NP, Llorente A. (2018). Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 75(2):193-208. 28733901. 2018. ↩︎
Bae EJ, et al. (2018). LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation. Nat Neurosci. 21(10):1440-1451. 30206222. 2018. ↩︎
Wang Y, et al. (2017). Neuronal exosomes and microRNAs in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 78:32-39. 28377282. 2017. ↩︎
Liu W, et al. (2018). Lipid composition of neuronal exosomes. J Lipid Res. 59(7):1254-1262. 29653952. 2018. ↩︎
Vella LJ, et al. (2017). The role of neuronal exosomes in neurodegeneration. Acta Neuropathol. 133(3):391-407. 28064356. 2017. ↩︎
Stuendl A, et al. (2016). Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease. Brain. 139(Pt 3):856-870. 26842773. 2016. ↩︎
Yuyama K, et al. (2015). Accelerated amyloid beta pathology in neurons derived from iPS cells carrying app mutation. Mol Brain. 8:69. 26400875. 2015. ↩︎
Bellingham SA, et al. (2012). Exosomes: novel biomarkers and therapeutic tools for neurodegenerative diseases. Gene Ther. 19(6):613-620. 22318089. 2012. ↩︎
Zetterström P, et al. (2011). ALS: a disorder of exosomes? Neurology. 77(8):761-762. 21832227. 2011. ↩︎
Croce KR, et al. (2019). Mutant huntingtin alters exosome cargo. Neurobiol Dis. 130:104516. 31229647. 2019. ↩︎
Sproviero D, et al. (2018). TDP-43 in extracellular vesicles from frontotemporal dementia. Exp Neurol. 307:125-132. 29870845. 2018. ↩︎
Howitt J, Hill AF. (2016). Exosomes in the pathology of neurodegenerative diseases. J Neurochem. 139(Suppl 1):198-215. 27797484. 2016. ↩︎
Kumar A, et al. (2020). Neuronal exosomes as biomarkers for neurodegenerative diseases. Adv Clin Chem. 98:73-91. 32600585. 2020. ↩︎
Carsanaro E, et al. (2021). Methods for analysis of neuronal exosomes in Alzheimer's disease. Mol Neurobiol. 58(12):6313-6324. 34448121. 2021. ↩︎